

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00455)**

## **VOLUNTARY ANNOUNCEMENT**

### **NEW R&D AND PRODUCTION BASE PUT INTO PRODUCTION**

This announcement is made by Tianda Pharmaceuticals Limited (the “**Company**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company and potential investors informed of the latest business development of the Company.

The Company is pleased to announce that it has recently put its new R&D and production base located in the Biomedicine Industrial Park in the Jinwan District of Zhuhai (the “**Zhuhai Base**”) into production. It is poised to become a pharmaceutical and health industry base with high standard, quality and efficiency.

The Zhuhai Base covers a total area of 96,000 square meters, with an investment of RMB390 million for the first phase of the development. The Company attaches great importance to innovation and R&D, and owns a number of invention patents. One of the products, the Valsartan capsules, which was rated as a famous high-tech product of Guangdong Province and a winner of the China Patent Award, passed the conformance assessment in 2020 and subsequently came in first place in the nation’s Third Round of Centralized Drug Procurement with Target Quantity. The Company has secured nationwide distribution for this product.

The Company continues to implement the strategies of “development of Chinese medicine as foundation, development of innovative drugs and medical technologies, as well as development of quality medical and healthcare services”, endeavouring to speed up product introduction and R&D, and boost business expansion and investment mergers and acquisitions. It strives to be a leading pharmaceutical enterprise setting its footholds in China and seeking to expand its presence worldwide.

*By order of the Board*  
**Tianda Pharmaceuticals Limited**  
**FANG Wen Quan**  
*Chairman and Managing Director*

Hong Kong, 10 May 2022

*As at the date of this announcement, the executive directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive directors are Mr. SHEN Bo and Mr. FENG Quanming; and the independent non-executive directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.*